
NEW YORK, June 22 (UPI) -- Neurocrine Biosciences is facing a U.S. shareholder class-action suit that alleges the firm misrepresented the chances of its sleep drug's approval.
Filed in the U.S. District Court for the Southern District of California, the suit charges Neurocrine violated federal securities laws because it "failed to disclose and misrepresented material adverse facts that related to the approval of Neurocrine's new anti-insomnia drug Indiplon by the Food and Drug Administration ..."
The complaint, filed on behalf of purchasers of Neurocrine common stock, accuses the company of hiding material information about the outcome of clinical studies of the insomnia treatment, leading investors to believe that approval of the drug by the Food and Drug Administration was "more likely than it was."
But last May, Neurocrine issued a press release saying the FDA "was not yet prepared to approve the most commercially viable form of Indiplon," sending the company's shares plummeting more than 60 percent, the suit charges.
|
|
|
|
|
|
| Additional Health News Stories | |
WASHINGTON, May 27 (UPI) --
President Obama has put U.S. foreign policy on auto-pilot while he concentrates on getting re-elected, a senior Republican senator said Sunday.
|
'Men in Black' leads U.S. box office ... Michelle Obama, daughters see Beyonce ... Lady Gaga cancels Jakarta gig for security ... Madonna asks for pool at Israel venue ... News from United Press International.
|
ANCHORAGE, Alaska, May 27 (UPI) --
A black bear didn't go over a river but went to the woods after scampering through residential and industrial areas of Anchorage, Alaska, police said.
|
To avoid a meltdown in 2006, Ford Motor Co. mortgaged the farm putting up its assets – including its Blue Oval logo, and F-150 pickup and iconic Mustang trademarks – to secure $23.5 billion in credit.
|
| Stories | Photos | People | Comments |
View Caption